HIV-specific T cell immunity

“HIV-specific T cell immunity” broadly refers to the adaptive immune response directed against HIV by T lymphocytes, primarily involving both CD4+ T helper cells and CD8+ cytotoxic T cells that recognize and respond to HIV antigens. This is not a molecular target, but rather a biological process or functional immune response. HIV-specific CD4+ T cells are crucial for orchestrating immune control and are associated with better disease outcomes in elite controllers, partly through cytokine secretion (such as IL-21) and providing help to CD8+ T cells[1][3][8]. HIV-specific CD8+ T cells mediate cytotoxic activity against infected cells and their quality and persistence inform vaccine and therapeutic strategies[2][4][5][9]. Both cell types can be impaired or exhausted during chronic HIV infection, which is characterized by increased expression of inhibitory receptors such as PD-1 and markers like FOXP3 on Treg cells, and loss of functional responses[1][6]. Although the loss or dysfunction of these responses facilitates disease progression, enhancing HIV-specific T cell responses is a focus of vaccine and immunotherapeutic research[4][5][10]. This concept should not be considered a discrete, singular target molecule or protein.

Other names

HIV-specific T cell responseHIV-specific CD4 T cellHIV-specific CD8 T cellHIV-specific immune responsesHIV-specific cellular immunity